Buyout firm GTCR is in advanced talks on a potential acquisition of German generic drugmaker Stada Arzneimittel AG, people ...

German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 ...

Rumours that German pharma Stada may be up for sale have been all but confirmed by the company's chief executive, who told a news agency that "exploratory talks" are taking place. Peter ...

Chicago-based buyout firm GTCR is in advanced talks on a potential acquisition of German generic drugmaker Stada Arzneimittel ...

(RTTNews) - Genpact Ltd. (G), an IT company, and Stada Arzneimittel AG (STDAY.PK, STDAF.PK), a maker of consumer healthcare, generic, and specialty pharma medicines, announced on Thursday that ...

Taking a closer look at the numbers, Stada’s specialty pharma arm grew sales 14% to 417.3 million euros ($464 million) during the first half of 2024. Stada credited the specialty pharma growth ...

Genpact (NYSE: G), a global professional services and solutions firm delivering outcomes that shape the future, and STADA (SAZ.DE), a leading manufacturer of consumer healthcare, generic and specialty ...

Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...

The European Commission has approved a biosimilar of the IL-12 and IL-23 inhibitor antibody developed by STADA and partner Alvotech – called Uzpurvo – for the treatment of plaque psoriasis ...

The yuan’s recent rally has limited room to extend as China’s economic woes may discourage the repatriation of dollar ...

Genpact Ltd. (G), an IT company, and Stada Arzneimittel AG (STDAY.PK, STDAF.PK), a maker of consumer healthcare, generic, and ...

Leveraging Genpact's data, technology and AI expertise to future-proof STADA's finance organization and drive competitive advantages NEW YORK, Sept. 12, 2024 /PRNewswire/ -- Genpact (NYSE ...